{"id":"https://openalex.org/W3043876549","doi":"https://doi.org/10.1080/14740338.2020.1798928","title":"Rationale and design of a European epidemiological post-authorization safety study (PASS) program: rivaroxaban use in routine clinical practice","display_name":"Rationale and design of a European epidemiological post-authorization safety study (PASS) program: rivaroxaban use in routine clinical practice","publication_year":2020,"publication_date":"2020-07-23","ids":{"openalex":"https://openalex.org/W3043876549","doi":"https://doi.org/10.1080/14740338.2020.1798928","mag":"3043876549","pmid":"https://pubmed.ncbi.nlm.nih.gov/32700977"},"language":"en","primary_location":{"id":"doi:10.1080/14740338.2020.1798928","doi":"https://doi.org/10.1080/14740338.2020.1798928","is_oa":true,"landing_page_url":"https://doi.org/10.1080/14740338.2020.1798928","pdf_url":"https://www.tandfonline.com/doi/pdf/10.1080/14740338.2020.1798928?needAccess=true","source":{"id":"https://openalex.org/S20709540","display_name":"Expert Opinion on Drug Safety","issn_l":"1474-0338","issn":["1474-0338","1744-764X"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-c","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-100","russia-white-list-2","vabb-shw"],"host_organization":"https://openalex.org/P4310320547","host_organization_name":"Taylor & Francis","host_organization_lineage":["https://openalex.org/P4310320547","https://openalex.org/P4310320449"],"host_organization_lineage_names":["Taylor & Francis","Informa"],"type":"journal"},"license":"cc-by-nc-nd","license_id":"https://openalex.org/licenses/cc-by-nc-nd","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Expert Opinion on Drug Safety","raw_type":"journal-article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":true,"oa_status":"hybrid","oa_url":"https://www.tandfonline.com/doi/pdf/10.1080/14740338.2020.1798928?needAccess=true","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5002455373","display_name":"Luis Alberto Garc\u00eda Rodr\u00edguez","orcid":"https://orcid.org/0000-0003-0837-2709","observed_orcids":["https://orcid.org/0000-0003-0837-2709"]},"institutions":[{"id":"https://openalex.org/I4210117725","display_name":"Centro Espa\u00f1ol de Investigaci\u00f3n Farmacoepidemiol\u00f3gica","ror":"https://ror.org/02wxe0t87","country_code":"ES","type":"facility","lineage":["https://openalex.org/I4210117725"]}],"countries":["ES"],"is_corresponding":true,"raw_author_name":"Luis Alberto Garc\u00eda-Rodr\u00edguez","raw_affiliation_strings":["Spanish Centre for Pharmacoepidemiologic Research (CEIFE), Madrid, Spain"],"raw_orcid":"https://orcid.org/0000-0003-0837-2709","affiliations":[{"raw_affiliation_string":"Spanish Centre for Pharmacoepidemiologic Research (CEIFE), Madrid, Spain","institution_ids":["https://openalex.org/I4210117725"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5049103522","display_name":"Mari-Ann A. Wallander","orcid":"https://orcid.org/0000-0002-8597-743X","observed_orcids":["https://orcid.org/0000-0002-8597-743X"]},"institutions":[{"id":"https://openalex.org/I123387679","display_name":"Uppsala University","ror":"https://ror.org/048a87296","country_code":"SE","type":"education","lineage":["https://openalex.org/I123387679"]}],"countries":["SE"],"is_corresponding":false,"raw_author_name":"Mari-Ann Wallander","raw_affiliation_strings":["Department of Public Health and Caring Sciences, Uppsala University, Uppsala, Sweden"],"raw_orcid":"https://orcid.org/0000-0002-8597-743X","affiliations":[{"raw_affiliation_string":"Department of Public Health and Caring Sciences, Uppsala University, Uppsala, Sweden","institution_ids":["https://openalex.org/I123387679"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5035052474","display_name":"Leif Friberg","orcid":"https://orcid.org/0000-0002-7453-0157","observed_orcids":["https://orcid.org/0000-0002-7453-0157"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Leif Friberg","raw_affiliation_strings":["Friberg Research AB, Stockholm, Sweden"],"raw_orcid":"https://orcid.org/0000-0002-7453-0157","affiliations":[{"raw_affiliation_string":"Friberg Research AB, Stockholm, Sweden","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5055013178","display_name":"Ana Ruig\u00f3mez","orcid":"https://orcid.org/0000-0002-9717-6306","observed_orcids":["https://orcid.org/0000-0002-9717-6306"]},"institutions":[{"id":"https://openalex.org/I4210117725","display_name":"Centro Espa\u00f1ol de Investigaci\u00f3n Farmacoepidemiol\u00f3gica","ror":"https://ror.org/02wxe0t87","country_code":"ES","type":"facility","lineage":["https://openalex.org/I4210117725"]}],"countries":["ES"],"is_corresponding":false,"raw_author_name":"Ana Ruigomez","raw_affiliation_strings":["Spanish Centre for Pharmacoepidemiologic Research (CEIFE), Madrid, Spain"],"raw_orcid":"https://orcid.org/0000-0002-9717-6306","affiliations":[{"raw_affiliation_string":"Spanish Centre for Pharmacoepidemiologic Research (CEIFE), Madrid, Spain","institution_ids":["https://openalex.org/I4210117725"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5032192131","display_name":"Tania Schink","orcid":"https://orcid.org/0000-0002-0224-1866","observed_orcids":["https://orcid.org/0000-0002-0224-1866","https://orcid.org/0000-0003-2252-1475"]},"institutions":[{"id":"https://openalex.org/I4210113759","display_name":"Leibniz Institute for Prevention Research and Epidemiology - BIPS","ror":"https://ror.org/02c22vc57","country_code":"DE","type":"facility","lineage":["https://openalex.org/I315704651","https://openalex.org/I4210113759"]}],"countries":["DE"],"is_corresponding":false,"raw_author_name":"Tania Schink","raw_affiliation_strings":["Leibniz Institute for Prevention Research and Epidemiology \u2013 BIPS, Bremen, Germany"],"raw_orcid":"https://orcid.org/0000-0002-0224-1866","affiliations":[{"raw_affiliation_string":"Leibniz Institute for Prevention Research and Epidemiology \u2013 BIPS, Bremen, Germany","institution_ids":["https://openalex.org/I4210113759"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5017820644","display_name":"Irene D. Bezemer","orcid":"https://orcid.org/0000-0003-4719-1142","observed_orcids":["https://orcid.org/0000-0003-4719-1142"]},"institutions":[{"id":"https://openalex.org/I4210120609","display_name":"Pharmo Institute","ror":"https://ror.org/01wfg6h04","country_code":"NL","type":"facility","lineage":["https://openalex.org/I4210120609"]}],"countries":["NL"],"is_corresponding":false,"raw_author_name":"Irene Bezemer","raw_affiliation_strings":["PHARMO Institute for Drug Outcomes Research, Utrecht, Netherlands"],"raw_orcid":"https://orcid.org/0000-0003-4719-1142","affiliations":[{"raw_affiliation_string":"PHARMO Institute for Drug Outcomes Research, Utrecht, Netherlands","institution_ids":["https://openalex.org/I4210120609"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5071030647","display_name":"Ron M. C. Herings","orcid":"https://orcid.org/0000-0002-2561-8734","observed_orcids":["https://orcid.org/0000-0002-2561-8734"]},"institutions":[{"id":"https://openalex.org/I4210120609","display_name":"Pharmo Institute","ror":"https://ror.org/01wfg6h04","country_code":"NL","type":"facility","lineage":["https://openalex.org/I4210120609"]}],"countries":["NL"],"is_corresponding":false,"raw_author_name":"Ron Herings","raw_affiliation_strings":["PHARMO Institute for Drug Outcomes Research, Utrecht, Netherlands"],"raw_orcid":"https://orcid.org/0000-0002-2561-8734","affiliations":[{"raw_affiliation_string":"PHARMO Institute for Drug Outcomes Research, Utrecht, Netherlands","institution_ids":["https://openalex.org/I4210120609"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5004126637","display_name":"Saad Shakir","orcid":"https://orcid.org/0000-0002-4084-297X","observed_orcids":["https://orcid.org/0000-0002-4084-297X"]},"institutions":[{"id":"https://openalex.org/I4210140975","display_name":"Drug Safety Research Unit","ror":"https://ror.org/04a8rag37","country_code":"GB","type":"nonprofit","lineage":["https://openalex.org/I4210140975"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Saad Shakir","raw_affiliation_strings":["Drug Safety Research Unit (DSRU), Southampton, UK"],"raw_orcid":"https://orcid.org/0000-0002-4084-297X","affiliations":[{"raw_affiliation_string":"Drug Safety Research Unit (DSRU), Southampton, UK","institution_ids":["https://openalex.org/I4210140975"]}]},{"author_position":"middle","author":{"id":null,"display_name":"Alison Evans","orcid":"https://orcid.org/0000-0003-1878-2429","observed_orcids":["https://orcid.org/0000-0003-1878-2429"]},"institutions":[{"id":"https://openalex.org/I4210140975","display_name":"Drug Safety Research Unit","ror":"https://ror.org/04a8rag37","country_code":"GB","type":"nonprofit","lineage":["https://openalex.org/I4210140975"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Alison Evans","raw_affiliation_strings":["Drug Safety Research Unit (DSRU), Southampton, UK"],"raw_orcid":"https://orcid.org/0000-0003-1878-2429","affiliations":[{"raw_affiliation_string":"Drug Safety Research Unit (DSRU), Southampton, UK","institution_ids":["https://openalex.org/I4210140975"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5010753379","display_name":"Miranda Davies","orcid":"https://orcid.org/0000-0003-2949-8378","observed_orcids":["https://orcid.org/0000-0003-2949-8378"]},"institutions":[{"id":"https://openalex.org/I4210140975","display_name":"Drug Safety Research Unit","ror":"https://ror.org/04a8rag37","country_code":"GB","type":"nonprofit","lineage":["https://openalex.org/I4210140975"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Miranda Davies","raw_affiliation_strings":["Drug Safety Research Unit (DSRU), Southampton, UK"],"raw_orcid":"https://orcid.org/0000-0003-2949-8378","affiliations":[{"raw_affiliation_string":"Drug Safety Research Unit (DSRU), Southampton, UK","institution_ids":["https://openalex.org/I4210140975"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5089190537","display_name":"Kiliana Suzart\u2010Woischnik","orcid":"https://orcid.org/0000-0002-3189-6378","observed_orcids":["https://orcid.org/0000-0002-3189-6378"]},"institutions":[{"id":"https://openalex.org/I67348948","display_name":"Bayer (Germany)","ror":"https://ror.org/04hmn8g73","country_code":"DE","type":"company","lineage":["https://openalex.org/I67348948"]}],"countries":["DE"],"is_corresponding":false,"raw_author_name":"Kiliana Suzart-Woischnik","raw_affiliation_strings":["Epidemiology, Bayer AG, Berlin, Germany"],"raw_orcid":"https://orcid.org/0000-0002-3189-6378","affiliations":[{"raw_affiliation_string":"Epidemiology, Bayer AG, Berlin, Germany","institution_ids":["https://openalex.org/I67348948"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5003994052","display_name":"Pareen Vora","orcid":"https://orcid.org/0000-0002-5822-2453","observed_orcids":["https://orcid.org/0000-0002-5822-2453"]},"institutions":[{"id":"https://openalex.org/I67348948","display_name":"Bayer (Germany)","ror":"https://ror.org/04hmn8g73","country_code":"DE","type":"company","lineage":["https://openalex.org/I67348948"]}],"countries":["DE"],"is_corresponding":false,"raw_author_name":"Pareen Vora","raw_affiliation_strings":["Epidemiology, Bayer AG, Berlin, Germany"],"raw_orcid":"https://orcid.org/0000-0002-5822-2453","affiliations":[{"raw_affiliation_string":"Epidemiology, Bayer AG, Berlin, Germany","institution_ids":["https://openalex.org/I67348948"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5034233892","display_name":"Yanina Balabanova","orcid":"https://orcid.org/0000-0002-5065-4788","observed_orcids":["https://orcid.org/0000-0002-5065-4788"]},"institutions":[{"id":"https://openalex.org/I67348948","display_name":"Bayer (Germany)","ror":"https://ror.org/04hmn8g73","country_code":"DE","type":"company","lineage":["https://openalex.org/I67348948"]}],"countries":["DE"],"is_corresponding":false,"raw_author_name":"Yanina Balabanova","raw_affiliation_strings":["Epidemiology, Bayer AG, Berlin, Germany"],"raw_orcid":"https://orcid.org/0000-0002-5065-4788","affiliations":[{"raw_affiliation_string":"Epidemiology, Bayer AG, Berlin, Germany","institution_ids":["https://openalex.org/I67348948"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5053686578","display_name":"Montse Soriano\u2010Gabarr\u00f3","orcid":"https://orcid.org/0000-0002-3825-0182","observed_orcids":["https://orcid.org/0000-0002-3825-0182"]},"institutions":[{"id":"https://openalex.org/I67348948","display_name":"Bayer (Germany)","ror":"https://ror.org/04hmn8g73","country_code":"DE","type":"company","lineage":["https://openalex.org/I67348948"]}],"countries":["DE"],"is_corresponding":false,"raw_author_name":"Montse Soriano-Gabarr\u00f3","raw_affiliation_strings":["Epidemiology, Bayer AG, Berlin, Germany"],"raw_orcid":"https://orcid.org/0000-0002-3825-0182","affiliations":[{"raw_affiliation_string":"Epidemiology, Bayer AG, Berlin, Germany","institution_ids":["https://openalex.org/I67348948"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5031838211","display_name":"Gunnar Brobert","orcid":"https://orcid.org/0000-0002-7446-9851","observed_orcids":["https://orcid.org/0000-0002-7446-9851"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Gunnar Brobert","raw_affiliation_strings":["Epidemiology, Bayer AB, Solna, Sweden"],"raw_orcid":"https://orcid.org/0000-0002-7446-9851","affiliations":[{"raw_affiliation_string":"Epidemiology, Bayer AB, Solna, Sweden","institution_ids":[]}]}],"institutions":[],"countries_distinct_count":5,"institutions_distinct_count":6,"corresponding_author_ids":["https://openalex.org/A5002455373"],"corresponding_institution_ids":["https://openalex.org/I4210117725"],"apc_list":null,"apc_paid":null,"fwci":0.5219,"has_fulltext":true,"cited_by_count":6,"citation_normalized_percentile":{"value":0.56386775,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":87,"max":95},"biblio":{"volume":"19","issue":"11","first_page":"1513","last_page":"1520"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11943","display_name":"Pharmacovigilance and Adverse Drug Reactions","score":0.9901999831199646,"subfield":{"id":"https://openalex.org/subfields/3005","display_name":"Toxicology"},"field":{"id":"https://openalex.org/fields/30","display_name":"Pharmacology, Toxicology and Pharmaceutics"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T11943","display_name":"Pharmacovigilance and Adverse Drug Reactions","score":0.9901999831199646,"subfield":{"id":"https://openalex.org/subfields/3005","display_name":"Toxicology"},"field":{"id":"https://openalex.org/fields/30","display_name":"Pharmacology, Toxicology and Pharmaceutics"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10285","display_name":"Venous Thromboembolism Diagnosis and Management","score":0.0035000001080334187,"subfield":{"id":"https://openalex.org/subfields/2724","display_name":"Internal Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10065","display_name":"Atrial Fibrillation Management and Outcomes","score":0.003100000089034438,"subfield":{"id":"https://openalex.org/subfields/2705","display_name":"Cardiology and Cardiovascular Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/rivaroxaban","display_name":"rivaroxaban","score":1.0},{"id":"https://openalex.org/keywords/factor-xa-inhibitors","display_name":"factor Xa inhibitors","score":0.9359999895095825},{"id":"https://openalex.org/keywords/post-authorization-safety-study","display_name":"post-authorization safety study","score":0.9070000052452087},{"id":"https://openalex.org/keywords/drug-safety","display_name":"drug safety","score":0.5659999847412109},{"id":"https://openalex.org/keywords/real-world-applications","display_name":"real-world applications","score":0.5189999938011169},{"id":"https://openalex.org/keywords/prescription-event-monitoring","display_name":"prescription-event monitoring","score":0.781000018119812},{"id":"https://openalex.org/keywords/medication-use","display_name":"medication use","score":0.5680000185966492},{"id":"https://openalex.org/keywords/risk-benefit-profile","display_name":"risk-benefit profile","score":0.8820000290870667},{"id":"https://openalex.org/keywords/venous-thromboembolism","display_name":"venous thromboembolism","score":0.7400000095367432},{"id":"https://openalex.org/keywords/health-databases","display_name":"health databases","score":0.5669999718666077},{"id":"https://openalex.org/keywords/observational-studies","display_name":"observational studies","score":0.4230000078678131}],"concepts":[{"id":"https://openalex.org/C2778661090","wikidata":"https://www.wikidata.org/wiki/Q420262","display_name":"Rivaroxaban","level":4,"score":0.8788059949874878},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.8652937412261963},{"id":"https://openalex.org/C2779343474","wikidata":"https://www.wikidata.org/wiki/Q3109175","display_name":"Context (archaeology)","level":2,"score":0.6122077703475952},{"id":"https://openalex.org/C23131810","wikidata":"https://www.wikidata.org/wiki/Q818574","display_name":"Observational study","level":2,"score":0.6098711490631104},{"id":"https://openalex.org/C107130276","wikidata":"https://www.wikidata.org/wiki/Q133805","display_name":"Epidemiology","level":2,"score":0.511436402797699},{"id":"https://openalex.org/C201903717","wikidata":"https://www.wikidata.org/wiki/Q1778788","display_name":"Cohort study","level":2,"score":0.4867563247680664},{"id":"https://openalex.org/C160735492","wikidata":"https://www.wikidata.org/wiki/Q31207","display_name":"Health care","level":2,"score":0.4578704833984375},{"id":"https://openalex.org/C72563966","wikidata":"https://www.wikidata.org/wiki/Q1303415","display_name":"Cohort","level":2,"score":0.4265991747379303},{"id":"https://openalex.org/C2426938","wikidata":"https://www.wikidata.org/wiki/Q3355478","display_name":"Medical prescription","level":2,"score":0.42089223861694336},{"id":"https://openalex.org/C535046627","wikidata":"https://www.wikidata.org/wiki/Q30612","display_name":"Clinical trial","level":2,"score":0.41032058000564575},{"id":"https://openalex.org/C512399662","wikidata":"https://www.wikidata.org/wiki/Q3505712","display_name":"Family medicine","level":1,"score":0.3284318447113037},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.14879873394966125},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.14799991250038147},{"id":"https://openalex.org/C2776301958","wikidata":"https://www.wikidata.org/wiki/Q407431","display_name":"Warfarin","level":3,"score":0.08470654487609863},{"id":"https://openalex.org/C2779161974","wikidata":"https://www.wikidata.org/wiki/Q815819","display_name":"Atrial fibrillation","level":2,"score":0.0},{"id":"https://openalex.org/C162324750","wikidata":"https://www.wikidata.org/wiki/Q8134","display_name":"Economics","level":0,"score":0.0},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.0},{"id":"https://openalex.org/C151730666","wikidata":"https://www.wikidata.org/wiki/Q7205","display_name":"Paleontology","level":1,"score":0.0},{"id":"https://openalex.org/C50522688","wikidata":"https://www.wikidata.org/wiki/Q189833","display_name":"Economic growth","level":1,"score":0.0}],"mesh":[{"descriptor_ui":"D000069552","descriptor_name":"Rivaroxaban","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D000069552","descriptor_name":"Rivaroxaban","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":true},{"descriptor_ui":"D005060","descriptor_name":"Europe","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D010818","descriptor_name":"Practice Patterns, Physicians'","qualifier_ui":"Q000706","qualifier_name":"statistics & numerical data","is_major_topic":false},{"descriptor_ui":"D011358","descriptor_name":"Product Surveillance, Postmarketing","qualifier_ui":null,"qualifier_name":null,"is_major_topic":true},{"descriptor_ui":"D011795","descriptor_name":"Surveys and Questionnaires","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D012107","descriptor_name":"Research Design","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D015331","descriptor_name":"Cohort Studies","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D016022","descriptor_name":"Case-Control Studies","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D016208","descriptor_name":"Databases, Factual","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D016907","descriptor_name":"Adverse Drug Reaction Reporting Systems","qualifier_ui":"Q000706","qualifier_name":"statistics & numerical data","is_major_topic":true},{"descriptor_ui":"D065427","descriptor_name":"Factor Xa Inhibitors","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D065427","descriptor_name":"Factor Xa Inhibitors","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":true}],"locations_count":5,"locations":[{"id":"doi:10.1080/14740338.2020.1798928","doi":"https://doi.org/10.1080/14740338.2020.1798928","is_oa":true,"landing_page_url":"https://doi.org/10.1080/14740338.2020.1798928","pdf_url":"https://www.tandfonline.com/doi/pdf/10.1080/14740338.2020.1798928?needAccess=true","source":{"id":"https://openalex.org/S20709540","display_name":"Expert Opinion on Drug Safety","issn_l":"1474-0338","issn":["1474-0338","1744-764X"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-c","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-100","russia-white-list-2","vabb-shw"],"host_organization":"https://openalex.org/P4310320547","host_organization_name":"Taylor & Francis","host_organization_lineage":["https://openalex.org/P4310320547","https://openalex.org/P4310320449"],"host_organization_lineage_names":["Taylor & Francis","Informa"],"type":"journal"},"license":"cc-by-nc-nd","license_id":"https://openalex.org/licenses/cc-by-nc-nd","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Expert Opinion on Drug Safety","raw_type":"journal-article"},{"id":"pmid:32700977","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/32700977","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Expert opinion on drug safety","raw_type":"Journal Article"},{"id":"pmh:oai:pure.amsterdamumc.nl:openaire/8fb16c1b-6cd9-41b3-877d-0cdef593afb0","doi":null,"is_oa":true,"landing_page_url":"https://pure.amsterdamumc.nl/en/publications/8fb16c1b-6cd9-41b3-877d-0cdef593afb0","pdf_url":null,"source":{"id":"https://openalex.org/S7407055222","display_name":"Pure Amsterdam UMC","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":null,"host_organization_name":null,"host_organization_lineage":[],"host_organization_lineage_names":[],"type":"repository"},"license":"other-oa","license_id":"https://openalex.org/licenses/other-oa","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Garcia-Rodriguez, L A, Wallander, M A, Friberg, L, Ruigomez, A, Schink, T, Bezemer, I, Herings, R, Shakir, S, Evans, A, Davies, M, Suzart-Woischnik, K, Vora, P, Balabanova, Y, Soriano-Gabarro, M & Brobert, G 2020, 'Rationale and design of a European epidemiological post-authorization safety study (PASS) program: rivaroxaban use in routine clinical practice', Expert opinion on drug safety, vol. 19, no. 11, pp. 1513-1520. https://doi.org/10.1080/14740338.2020.1798928","raw_type":"info:eu-repo/semantics/article"},{"id":"pmh:oai:frl.publisso.de:frl:6425802","doi":null,"is_oa":true,"landing_page_url":"https://www.tandfonline.com/doi/full/10.1080/14740338.2020.1798928","pdf_url":null,"source":{"id":"https://openalex.org/S4306402606","display_name":"Informationszentrum Lebenswissenschaften (ZB MED)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I4210112663","host_organization_name":"ZB MED - Information Centre for Life Sciences","host_organization_lineage":["https://openalex.org/I4210112663"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by-nc-nd","license_id":"https://openalex.org/licenses/cc-by-nc-nd","version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"Expert opinion on drug safety, 19(11):1513-1520","raw_type":"Zeitschriftenartikel"},{"id":"pmh:vumc:oai:pure.atira.dk:publications/2678d4a2-4f81-4c20-956c-4cc23def523a","doi":null,"is_oa":false,"landing_page_url":"https://research.vumc.nl/en/publications/2678d4a2-4f81-4c20-956c-4cc23def523a","pdf_url":null,"source":{"id":"https://openalex.org/S4306401843","display_name":"Data Archiving and Networked Services (DANS)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1322597698","host_organization_name":"Royal Netherlands Academy of Arts and Sciences","host_organization_lineage":["https://openalex.org/I1322597698"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"Expert opinion on drug safety, 19(11), 1513 - 1520. Taylor and Francis Ltd.","raw_type":"info:eu-repo/semantics/article"}],"best_oa_location":{"id":"doi:10.1080/14740338.2020.1798928","doi":"https://doi.org/10.1080/14740338.2020.1798928","is_oa":true,"landing_page_url":"https://doi.org/10.1080/14740338.2020.1798928","pdf_url":"https://www.tandfonline.com/doi/pdf/10.1080/14740338.2020.1798928?needAccess=true","source":{"id":"https://openalex.org/S20709540","display_name":"Expert Opinion on Drug Safety","issn_l":"1474-0338","issn":["1474-0338","1744-764X"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-c","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-100","russia-white-list-2","vabb-shw"],"host_organization":"https://openalex.org/P4310320547","host_organization_name":"Taylor & Francis","host_organization_lineage":["https://openalex.org/P4310320547","https://openalex.org/P4310320449"],"host_organization_lineage_names":["Taylor & Francis","Informa"],"type":"journal"},"license":"cc-by-nc-nd","license_id":"https://openalex.org/licenses/cc-by-nc-nd","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Expert Opinion on Drug Safety","raw_type":"journal-article"},"sustainable_development_goals":[{"display_name":"Good health and well-being","score":1.0,"id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[{"id":"https://openalex.org/F4320307771","display_name":"Bayer","ror":"https://ror.org/04hmn8g73"}],"has_content":{"pdf":true,"grobid_xml":true},"content_urls":{"pdf":"https://content.openalex.org/works/W3043876549.pdf","grobid_xml":"https://content.openalex.org/works/W3043876549.grobid-xml"},"referenced_works_count":35,"referenced_works":["https://openalex.org/W1839975480","https://openalex.org/W1917850483","https://openalex.org/W1979698089","https://openalex.org/W1983126671","https://openalex.org/W2013750247","https://openalex.org/W2040320160","https://openalex.org/W2049754426","https://openalex.org/W2097854437","https://openalex.org/W2101373584","https://openalex.org/W2109616392","https://openalex.org/W2113561246","https://openalex.org/W2115787552","https://openalex.org/W2117662968","https://openalex.org/W2117677020","https://openalex.org/W2118695883","https://openalex.org/W2124833686","https://openalex.org/W2130199362","https://openalex.org/W2137477398","https://openalex.org/W2138868169","https://openalex.org/W2164595809","https://openalex.org/W2165863996","https://openalex.org/W2166018731","https://openalex.org/W2185462452","https://openalex.org/W2225295868","https://openalex.org/W2508374812","https://openalex.org/W2639156993","https://openalex.org/W2749380187","https://openalex.org/W2777982354","https://openalex.org/W2810518551","https://openalex.org/W2946212138","https://openalex.org/W2954517587","https://openalex.org/W2971121646","https://openalex.org/W2989714602","https://openalex.org/W3004050106","https://openalex.org/W4237126685"],"related_works":["https://openalex.org/W2107583031","https://openalex.org/W2247775490","https://openalex.org/W4393203216","https://openalex.org/W2323002292","https://openalex.org/W2267852407","https://openalex.org/W2786501100","https://openalex.org/W2913595217","https://openalex.org/W4312284358","https://openalex.org/W3168107196","https://openalex.org/W7098210196"],"abstract_inverted_index":{"BACKGROUND:":[0],"Rivaroxaban":[1],"is":[2,161],"a":[3,80,107,162],"highly":[4],"selective":[5],"factor":[6],"Xa":[7],"inhibitor":[8],"approved":[9],"for":[10,14],"use":[11,62,132],"in":[12,47,74,91,98,114,119,133,152,173],"Europe":[13],"multiple":[15],"indications.":[16],"STUDY":[17],"DESIGN":[18],"AND":[19],"METHODS:":[20],"The":[21,156],"European":[22,157],"rivaroxaban":[23,61,78,131,158],"epidemiological":[24,159],"post-authorization":[25],"safety":[26,70,93,144],"study":[27,112],"(PASS)":[28],"program":[29,164],"consists":[30],"of":[31,38,60,77,101,103,165,182,186],"seven":[32],"complementary":[33,166],"observational":[34],"studies.":[35],"For":[36],"four":[37],"the":[39,48,50,115,134,153,183],"studies,":[40],"data":[41,145],"are":[42,95],"obtained":[43],"from":[44,170],"health-care":[45,150],"databases":[46],"UK,":[49],"Netherlands,":[51],"Germany,":[52],"and":[53,63,68,71,83,122,143],"Sweden.":[54],"These":[55],"database":[56],"studies":[57,128,167],"describe":[58],"patterns":[59],"patient":[64],"characteristics":[65],"over":[66],"time,":[67],"investigate":[69],"effectiveness":[72],"outcomes":[73,94],"new":[75,99],"users":[76,100],"using":[79],"cohort":[81,125],"analysis":[82],"nested":[84],"case-control":[85],"analysis.":[86],"To":[87],"put":[88],"these":[89],"results":[90],"context,":[92],"also":[96],"analyzed":[97],"standard":[102],"care.":[104],"In":[105],"addition,":[106],"modified":[108],"prescription":[109],"event":[110,126],"monitoring":[111,127],"conducted":[113],"early":[116],"post-launch":[117],"phase":[118],"primary":[120],"care,":[121],"two":[123],"specialist":[124],"that":[129,177],"investigated":[130],"secondary":[135],"care":[136],"hospital":[137],"setting,":[138],"systematically":[139],"collected":[140],"drug":[141],"utilization":[142],"via":[146],"questionnaires":[147],"completed":[148],"by":[149],"professionals":[151],"UK.":[154],"DISCUSSION:":[155],"PASS":[160],"comprehensive":[163],"generating":[168],"evidence":[169],"patients":[171],"treated":[172],"routine":[174],"clinical":[175],"practice":[176],"will":[178],"expand":[179],"our":[180],"understanding":[181],"risk-benefit":[184],"profile":[185],"rivaroxaban.":[187]},"counts_by_year":[{"year":2025,"cited_by_count":1},{"year":2024,"cited_by_count":2},{"year":2023,"cited_by_count":2},{"year":2021,"cited_by_count":1}],"updated_date":"2026-11-04T10:54:05.112534","created_date":"2020-07-29T00:00:00"}